Biological E Limited is celebrating a groundbreaking moment! The World Health Organization has officially granted phase II pre-qualification for their Novel Oral Polio Vaccine type 2. This significant ...

WHO prequalifies Biological E’s novel oral polio vaccine type 2, to strengthen global outbreak response: Our Bureau, Mumbai Saturday, February 14, 2026, 09:00 Hrs [IST] The Worl ...

“Takeda's long-term goal for our dengue program has been to make QDENGA broadly available to those at risk who may benefit from immunization. Within the last year, we've successfully launched in ...

IVI will complete the technology transfer by 2025 Oral Cholera Vaccine to be manufactured by Biological E. Limited for India and international markets March 20, 2024, SEOUL, Republic of Korea and ...

HYDERABAD, India and HOUSTON and EMERYVILLE, Calif., Nov. 16, 2020 /PRNewswire/ -- Biological E. Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, Dynavax Technologies Corporation ...

Jiangsu Recbio Technology Company Limited (02179.HK), announced that they have entered into a licensing cooperation agreement, and have commenced the technology transfer of their Recombinant 9-valent ...

Two recently-signed agreements will transfer Takeda’s measles and acellular pertussis vaccine technologies to India-based multi-national company Biological E. Limited (“BE”) to develop low-cost ...

Biological E Ltd. has partnered with Jiangsu Recbio Technology to commercialize the latter's HPV9 vaccine, REC603, in India. Recbio will supply the drug substance and technology for formulation and ...

NEW DELHI (Reuters) - India's Biological E. Ltd will soon start Phase III trials of its COVID-19 vaccine and plans producing 75 million to 80 million doses a month from August, its managing director ...

Hyderabad based Biological E. Limited (BE) on Thursday announced a major milestone in the global fight against polio, with the World Health Organization (WHO) granting Phase II Pre-Qualification (PQ) ...